This document discusses the use of nanocarriers for eye cancer treatment and management. It describes some common types of eye cancer and why nanocarriers are needed due to ocular barriers and risks of damage from repeated injection. The main nanocarriers discussed are liposomes, dendrimers, and carbon nanotubes, along with their advantages such as biocompatibility and drug encapsulation abilities. However, nanocarriers also have disadvantages like limited storage conditions and potential toxicity. In conclusion, the document evaluates nanocarrier strategies for delivering drugs to the eye in a targeted manner for cancer therapy.